Novartis AG NVS NYSE

Novartis AG (NVS) generated $19.24B in operating cash flow for fiscal year 2025. After capital expenditures of $1.56B, free cash flow was $17.69B.

Free cash flow margin was 32.3% of revenue. Cash conversion ratio was 1.37x, indicating earnings are backed by cash.

The company returned $7.86B in dividends and $9.26B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (94/100, Pass) — $17.69B (32.3% FCF margin) supports a durable competitive advantage
• INCOME (85/100) — Cash conversion ratio was 1.37x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 68/100 with 4/7 criteria passed.